AptarGroup (ATR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Mar, 2026Executive summary
The annual meeting is scheduled for May 6, 2026, to review 2025 performance and vote on director elections, executive compensation, and auditor ratification.
2025 saw record reported sales of $3.8 billion, $393 million net income, and $5.89 EPS, with total shareholder return lagging major indices but outperforming peers.
Leadership transition announced: Gael Touya to become CEO on September 1, 2026, succeeding Stephan B. Tanda, who will remain as strategic advisor through year-end.
Voting matters and shareholder proposals
Shareholders will vote on electing four directors to terms expiring in 2029, an advisory say-on-pay vote, and ratification of PricewaterhouseCoopers LLP as auditor for 2026.
Board recommends voting FOR all proposals.
Shareholder proposals for the 2027 meeting must be submitted by November 27, 2026.
Board of directors and corporate governance
Board consists of 10 members, 90% independent, with a separate independent Chair and CEO.
Committees (Audit, Management Development and Compensation, Corporate Governance) are 100% independent.
Annual board and committee self-evaluations, majority voting for directors, and director age limits in place.
Stock ownership guidelines require non-executive directors to hold shares worth at least five times the annual cash retainer.
Board diversity includes international experience, industry expertise, and a skills matrix covering leadership, finance, strategy, and sustainability.
Latest events from AptarGroup
- Annual meeting covers director elections, say-on-pay, and auditor ratification.ATR
Proxy filing27 Mar 2026 - Pharma-led innovation, sustainability, and disciplined capital drive robust 2025 results and outlook.ATR
47th Annual Raymond James Institutional Investor Conference6 Mar 2026 - 2025 growth led by pharma and innovation, with margin expansion and global operational strength.ATR
Bank of America 2026 Global Agriculture and Materials Conference2 Mar 2026 - Q4 2025 sales up 14% but net income down 26%; $486M returned to shareholders.ATR
Q4 20256 Feb 2026 - Profitable growth driven by innovation, efficiency, and strong shareholder returns.ATR
Investor Day 20253 Feb 2026 - Q2 adjusted EPS up 12% to $1.37, driven by Pharma growth and margin gains.ATR
Q2 20242 Feb 2026 - Q3 net income up 19% to $100M; Pharma and Closures drive growth, Beauty faces headwinds.ATR
Q3 202418 Jan 2026 - Pharma innovation, injectables, and digital health drive growth with balanced capital allocation.ATR
44th Annual J.P. Morgan Healthcare Conference16 Jan 2026 - Pharma leads growth with innovation, sustainability, and digital health, supporting raised targets.ATR
43rd Annual J.P. Morgan Healthcare Conference10 Jan 2026